Aristotle Capital Management LLC Sells 187,055 Shares of GSK plc (NYSE:GSK)

Aristotle Capital Management LLC trimmed its stake in GSK plc (NYSE:GSK - Free Report) by 10.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,601,320 shares of the pharmaceutical company's stock after selling 187,055 shares during the period. Aristotle Capital Management LLC owned 0.08% of GSK worth $54,157,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. FMR LLC lifted its position in shares of GSK by 82.1% during the fourth quarter. FMR LLC now owns 52,823,032 shares of the pharmaceutical company's stock valued at $1,786,475,000 after buying an additional 23,814,104 shares during the last quarter. Primecap Management Co. CA lifted its position in GSK by 70.1% during the fourth quarter. Primecap Management Co. CA now owns 25,261,660 shares of the pharmaceutical company's stock valued at $854,349,000 after acquiring an additional 10,407,905 shares during the last quarter. Bridgewater Associates LP boosted its stake in GSK by 132.7% in the fourth quarter. Bridgewater Associates LP now owns 2,247,691 shares of the pharmaceutical company's stock valued at $76,017,000 after acquiring an additional 1,281,855 shares in the last quarter. Schonfeld Strategic Advisors LLC grew its holdings in GSK by 68.2% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 2,237,034 shares of the pharmaceutical company's stock worth $75,656,000 after purchasing an additional 907,068 shares during the last quarter. Finally, Mondrian Investment Partners LTD increased its position in shares of GSK by 17.6% during the fourth quarter. Mondrian Investment Partners LTD now owns 5,838,384 shares of the pharmaceutical company's stock worth $205,920,000 after purchasing an additional 874,004 shares in the last quarter. Institutional investors own 15.74% of the company's stock.

Wall Street Analyst Weigh In

GSK has been the topic of several research analyst reports. StockNews.com upgraded GSK from a "buy" rating to a "strong-buy" rating in a research note on Thursday, April 24th. BNP Paribas initiated coverage on GSK in a research note on Tuesday, April 15th. They set a "neutral" rating and a $35.25 price target on the stock. Hsbc Global Res upgraded shares of GSK to a "strong sell" rating in a research note on Monday, April 28th. Finally, Morgan Stanley initiated coverage on shares of GSK in a research report on Wednesday, February 12th. They set an "equal weight" rating on the stock. One analyst has rated the stock with a sell rating, eight have issued a hold rating and four have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $40.58.

GSK Stock Up 0.7 %

GSK stock opened at $39.04 on Friday. The company has a market capitalization of $80.55 billion, a P/E ratio of 24.55, a price-to-earnings-growth ratio of 1.12 and a beta of 0.56. GSK plc has a 12 month low of $31.72 and a 12 month high of $45.93. The firm's fifty day simple moving average is $37.68 and its 200-day simple moving average is $36.04. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.52.

GSK (NYSE:GSK - Get Free Report) last posted its quarterly earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 EPS for the quarter, beating the consensus estimate of $1.08 by $0.05. The company had revenue of $10.06 billion for the quarter, compared to analyst estimates of $7.52 billion. GSK had a net margin of 8.13% and a return on equity of 48.59%. The firm's revenue was up 2.1% on a year-over-year basis. During the same period in the prior year, the company earned $0.43 earnings per share. As a group, equities research analysts forecast that GSK plc will post 4.14 earnings per share for the current year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 10th. Shareholders of record on Friday, May 16th will be given a $0.4216 dividend. This represents a $1.69 annualized dividend and a yield of 4.32%. The ex-dividend date of this dividend is Friday, May 16th. This is a positive change from GSK's previous quarterly dividend of $0.39. GSK's dividend payout ratio is currently 100.63%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.